Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition

Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition 
MONTREAL, Nov. 16, 2012 /CNW/ - Valeant Pharmaceuticals International, Inc. 
(NYSE: VRX and TSX: VRX) announced today that the U.S. Federal Trade 
Commission (FTC) has completed its review of the proposed acquisition of 
Medicis Pharmaceutical Corporation (NYSE: MRX) by Valeant and has granted 
early termination of the waiting period under the Hart-Scott-Rodino Antitrust 
Improvements Act of 1976 (HSR) without conditions. The grant of early 
termination is effective as of November 15, 2012. 
The proposed merger remains subject to other customary closing conditions, 
including the approval of the Medicis's stockholders at its special meeting of 
stockholders scheduled for December 7, 2012.  The Company expects to close the 
merger within four business days following satisfaction of all closing 
conditions. 
About Valeant Pharmaceuticals International, Inc. 
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational 
specialty pharmaceutical company that develops, manufactures and markets a 
broad range of pharmaceutical products primarily in the areas of neurology, 
dermatology and branded generics.  More information about Valeant 
Pharmaceuticals International, Inc. can be found at www.valeant.com. 
Forward-Looking Statements 
These forward-looking statements relate to, among other things, the expected 
timing of the close of the transaction.  Forward-looking statements can 
generally be identified by the use of words such as "believe", "anticipate", 
"expect", "estimate", "intend", "continue", "plan", "project", "will", "may", 
"should", "could", "would", "target", "potential" and other similar 
expressions.  In addition, any statements that refer to expectations, 
projections or other characterizations of future events or circumstances are 
forward-looking statements.  Actual results may differ materially from those 
expressed or implied in such statements.  Important factors that could cause 
actual results to differ materially from these expectations include, among 
other things, the expected timing of the close of the transaction and the 
satisfaction of the closing conditions to the transaction, and the risk 
factors as detailed from time to time in Valeant's reports filed with the 
Securities and Exchange Commission ("SEC") and the Canadian Securities 
Administrators ("CSA"). 
Contact Information:  Laurie W. Little  949-461-6002  laurie.little@valeant.com 
(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO) 
http://www.valeant.com 
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Valeant Pharmaceuticals International, Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/November2012/16/c8847.html 
CO: Valeant Pharmaceuticals International, Inc.
ST: Quebec
NI: HEA MTC MNA  
-0- Nov/16/2012 12:52 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.